Stifel Nicolaus maintained Theravance (NASDAQ: THRX ) with a Buy rating and lowered the price target from $40.00 to $37.00. Stifel Nicolaus commented, "We expect the release of BREO briefing docs (likely March 4th/5th) and subsequent PADAC meeting to likely generate a meaningful amount of volatility in the stock. However,